Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Erbitux (ImClone Systems Inc): Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Erbitux (ImClone Systems Inc) - General Information

Epidermal growth factor receptor binding FAB. Erbitux (ImClone Systems Inc) is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.

 

Pharmacology of Erbitux (ImClone Systems Inc)

Used in the treatment of colorectal cancer, Erbitux binds specifically to the epidermal growth factor receptor (EGFr, HER1, c-ErbB-1) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Erbitux competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor–alpha. Binding of Erbitux to the EGFr blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased matrix metalloproteinase secretion and reduced vascular endothelial growth factor production.

 

Erbitux (ImClone Systems Inc) for patients

 

Erbitux (ImClone Systems Inc) Interactions

A drug interaction study was performed in which ERBITUX was administered in combination with irinotecan. There was no evidence of any pharmacokinetic interactions between ERBITUX and irinotecan.

 

Erbitux (ImClone Systems Inc) Contraindications

None.

 

Additional information about Erbitux (ImClone Systems Inc)

Erbitux (ImClone Systems Inc) Indication: For treatment of metastatic colorectal cancer Mechanism Of Action: Erbitux binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Erbitux competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread. Drug Interactions: Not Available Food Interactions: Not Available Generic Name: Cetuximab Synonyms: Anti EGFR; Ig gamma-1 chain C region Drug Category: Antineoplastic Agents Drug Type: Biotech; Approved; Investigational Other Brand Names containing Cetuximab: Erbitux (ImClone Systems Inc); Erbitux; Absorption: Not Available Toxicity (Overdose): Not Available Protein Binding: Not Available Biotransformation: Not Available Half Life: 114 hrs Dosage Forms of Erbitux (ImClone Systems Inc): Solution Intravenous Chemical IUPAC Name: Humanized anti-EGF receptor (EGFr) antibody Chemical Formula: C6484H10042N1732O2023S36 Cetuximab on Wikipedia: https://en.wikipedia.org/wiki/Cetuximab Organisms Affected: Humans and other mammals